Direct acting antivirals (DAAs) have revolutionized treatment for hepatitis C. Combi-
nations of DAAs can cure infection with HCV in 12 weeks, are highly effective and
have limited side-effects. Affordability of DAAs has improved significantly, but access remains lim-
i...ted. Initially, due to their high prices, affordability of DAAs was limited in high-, middle- and low-
income countries alike. Now there is a divide between those countries where, because of intellectual
property barriers, prices have remained (very) high and other countries where generics are, or can be,
available at much lower prices. The result is a dual market
more
A survival guide for clinicans.
3rd edition.
Ensuring Access to Simple, Safe and Effective First-Line Medicines for Tuberculosis.
Accessed in November 2017.
Lessons from the STEP-TB Project.
Accessed November 2017.
Best Practice for the Care of Patients with Tuberculosis: a Guide for Low-Income CountriesThe practical aspects of TB patient care from the onset of symptoms to the completion of treatment are covered in this guide.
PLOS ONE | DOI:10.1371/journal.pone.0133869 July 28, 2015, p.1-16
This guidance is intended for use in developing standalone TB strategic plans, or TB interventions as part of multidisease or health sector plans. It describes key considerations and steps for strategic planning for TB in line with the World Health Organization’s End TB strategy, and the proposed ...structure of the NSP. The target audience of this publication are all stakeholders involved in national strategic planning for TB (e.g., ministry of health, other government ministries, private sector, civil society, affected communities, academic and research institutions, and technical and funding partners).
The current document is an update to the 2015 Toolkit to develop a national strategic plan for TB prevention, care and control.
more
For Children and their Families
October 2015
The 23rd meeting of the WHO Expert Committee on Selection and Use of Essential Medicines was coordinated from Geneva, Switzerland, and held virtually from 21 June to 2 July 2021. The Committee considered 88 applications proposing additions, changes and deletions of medicines, medicine classes and fo...rmulations on the Model Lists of Essential Medicines. The Committee evaluated the scientific evidence for comparative effectiveness, safety and cost-effectiveness of the medicines in question. The Committee also considered a review of the therapeutic alternatives for medicines on the Model Lists, and update to the AWaRe classification of antibiotics, and reviews and reports relevant to the selection and use of essential medicines.
more
Key populations brief
Accessed 2017
Journal of Pulmonary & Respiratory Medicine 6: 326. doi:10.4172/2161-105X.1000326
A manual for programme managers.
БОРЬБА С ТУБЕРКУЛЕЗОМ В ТЮРЬМАХ
Руководство для руководителей программ
Manual para directores de programas
Scientific advice
Prevention and control of communicable diseases in prison settings.
Morbidity and Mortality Weekly Report
Recommendations and Reports: July 7, 2006 / Vol. 55 / No. RR-9